Crossmark Global Holdings Inc. Acquires 9,781 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Crossmark Global Holdings Inc. grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 328.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,760 shares of the company’s stock after purchasing an additional 9,781 shares during the period. Crossmark Global Holdings Inc.’s holdings in Dr. Reddy’s Laboratories were worth $201,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of RDY. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Dr. Reddy’s Laboratories by 318.0% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock worth $28,411,000 after purchasing an additional 283,700 shares in the last quarter. Artemis Investment Management LLP increased its holdings in shares of Dr. Reddy’s Laboratories by 398.3% in the fourth quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock worth $4,666,000 after purchasing an additional 236,224 shares during the period. Fisher Asset Management LLC raised its position in shares of Dr. Reddy’s Laboratories by 59.4% in the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock worth $39,034,000 after buying an additional 183,146 shares in the last quarter. Millennium Management LLC boosted its stake in Dr. Reddy’s Laboratories by 61.4% during the second quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after buying an additional 126,472 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Dr. Reddy’s Laboratories by 219.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock worth $12,353,000 after buying an additional 106,796 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on RDY shares. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Finally, Barclays reduced their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Price Performance

RDY opened at $13.66 on Tuesday. The company’s 50-day simple moving average is $14.86 and its two-hundred day simple moving average is $15.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. The stock has a market capitalization of $11.40 billion, a P/E ratio of 21.81 and a beta of 0.51. Dr. Reddy’s Laboratories Limited has a 52-week low of $13.59 and a 52-week high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%. As a group, analysts predict that Dr. Reddy’s Laboratories Limited will post 0.81 EPS for the current year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.